FDA Approved Products

1,302 products with lifecycle intelligence, competitive pressure scores, and patent timelines.

Type:AllNDABLAANDA
Lifecycle:GrowthPeakLOE ApproachingPost-LOELaunchPre-Launch
Sort:Approval DateNameCompetitive Pressure↓
Active:Lifecycle: PeakClear all
VANCOMYCIN
vancomycin
Peak
Hikma
INTRAVENOUS, ORAL · SOLUTION
2021
NDA
0/100
VARITHENA
polidocanol
Peak
INTRAVENOUS · SOLUTION
2013
NDA
0/100
VARUBI
rolapitant hydrochloride
Peak
TerSera Therapeutics
INTRAVENOUS · EMULSION
2017
NDA
0/100
VASCEPA
icosapent ethyl
Peak
Inpharmus
ORAL · CAPSULE
2012
NDA
0/100
VASOSTRICT
vasopressin
Peak
Pfizer
INTRAVENOUS · SOLUTION
2014
NDA
0/100
VAZALORE
aspirin
Peak
ORAL · CAPSULE
2013
NDA
0/100
VEKLURY
remdesivir
Peak
Gilead Sciences
INTRAVENOUS · SOLUTION
coronavirus disease 2019 (COVID-19) in adults
2020
SMNDA
0/100
VELPHORO
sucroferric oxyhydroxide
Peak
Fresenius Kabi
ORAL · TABLET, CHEWABLE
2013
NDA
0/100
VELTASSA
patiromer
Peak
ORAL · POWDER
2015
NDA
0/100
VEMLIDY
tenofovir alafenamide
Peak
Gilead Sciences
ORAL · TABLET
chronic hepatitis B virus infection in adultsolder+2
2016
NDA
0/100
VENCLEXTA
venetoclax
Peak
AbbVie
ORAL · TABLET
2016
NDA
0/100
VERQUVO
vericiguat
Peak
Merck & Co.
ORAL · TABLET
2021
NDA
0/100
VERZENIO
abemaciclib
Peak
Eli Lilly and Company
ORAL · TABLET
2017
SMNDA
0/100
VESICARE LS
solifenacin succinate
Peak
Astellas
ORAL · SUSPENSION
neurogenic detrusor overactivity in pediatric patients aged 2 yearsolder
2020
NDA
0/100
VIBERZI
eluxadoline
Peak
AbbVie
ORAL · TABLET
2015
NDA
0/100
VICTOZA
liraglutide
Peak
Novo Nordisk
SUBCUTANEOUS · SOLUTION
2010
PeptideNDA
0/100
VIEKIRA PAK (COPACKAGED)
dasabuvir sodium; ombitasvir, paritaprevir, ritonavir
Peak
AbbVie
ORAL · TABLET
2014
SMNDA
0/100
VIEKIRA XR
dasabuvir sodium; ombitasvir; paritaprevir; ritonavir
Peak
AbbVie
ORAL · TABLET, EXTENDED RELEASE
2016
SMNDA
0/100
VIJOICE
alpelisib
Peak
Novartis
ORAL · TABLET
older with severe manifestations of PIK3CA-Related Overgrowth Spectrum (PROS)
2022
SMNDA
0/100
VILTEPSO
viltolarsen
Peak
Nippon Shinyaku
INTRAVENOUS · SOLUTION
2020
RNANDA
0/100
VITRAKVI
larotrectinib
Peak
Bayer
ORAL · CAPSULE
2018
SMNDA
0/100
VITRAKVI
larotrectinib
Peak
Bayer
ORAL · SOLUTION
2018
SMNDA
0/100
VIVIMUSTA
bendamustine hydrochloride
Peak
R-Pharm US
INTRAVENOUS · SOLUTION
2022
NDA
0/100
VIVJOA
oteseconazole
Peak
Mycovia Pharmaceuticals
ORAL · CAPSULE
2022
SMNDA
0/100
← PreviousPage 51 of 55Next →